Reprogram Biosciences, a preclinical oncology company based in San Carlos, California, has closed a seed financing round that brings total capital raised to USD 6 million since the company's founding in 2025, with proceeds directed toward its lead intratumoral mRNA reprogramming program and AI-driven discovery engine.
The Reprogram Biosciences seed funding drew participation from Unshackled Ventures, 1517 Fund, and Narya, with no single investor designated as lead in the company's announcement. Proceeds will support continued preclinical development of the company's lead program, chemistry, manufacturing, and controls activities, and expansion of its CellRecodeX AI discovery engine. The company's earlier capitalization, reflected in a Form D filing with the SEC in May 2025, raised USD 1 million from three investors, representing the initial tranche of capital ahead of the broader seed close.
Reprogram Biosciences is developing mRNA-based therapeutics designed to reprogram tumor cells into antigen-presenting cells directly within the tumor. The approach involves delivering mRNA-encoded gene combinations intratumorally to induce antigen-presenting function in cancer cells, with the aim of converting an immunosuppressive tumor microenvironment into a site of active immune priming capable of generating systemic antitumor responses.
The scientific basis for this strategy draws on research demonstrating that specific transcription factor combinations — including PU.1, IRF8, and BATF3 — can reprogram tumor cells into type 1 conventional dendritic cell-like states that present tumor antigens on MHC class I and II molecules and express co-stimulatory signals required for T cell activation. Reprogram's use of mRNA rather than viral vectors is intended to provide a transient, non-integrating reprogramming signal localized to the tumor site.
The company's lead program remains unnamed in its public disclosures. No clinical trial registrations attributable to Reprogram Biosciences were available at the time of this article, consistent with its preclinical stage.